Do analysts prefer RDY or ATAI?

Atai Beckley has a consensus target price of $11.06, suggesting a potential upside of 54.09%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts plainly believe Atai Beckley is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Atai Beckley 1 Sell rating(s) 11 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.27

Does the media favor RDY or ATAI?

In the previous week, Dr. Reddy's Laboratories had 8 more articles in the media than Atai Beckley. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 1 mentions for Atai Beckley. Dr. Reddy's Laboratories' average media sentiment score of 0.54 beat Atai Beckley's score of 0.44 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRNX or ATAI?

In the previous week, Crinetics Pharmaceuticals had 11 more articles in the media than Atai Beckley. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 1 mentions for Atai Beckley. Crinetics Pharmaceuticals' average media sentiment score of 0.51 beat Atai Beckley's score of 0.44 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Atai Beckley 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ATAI or ALKS?

Alkermes has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 645.87 -$660.05M -$2.23 N/A Alkermes $1.67B 4.94 $241.66M $0.38 129.33

Is ATAI or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Atai Beckley's net margin of -19,019.44%. Alkermes' return on equity of 4.15% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -19,019.44% -89.79% -63.58% Alkermes 3.96% 4.15% 2.19%

Does the media refer more to ATAI or ALKS?

In the previous week, Alkermes had 40 more articles in the media than Atai Beckley. MarketBeat recorded 41 mentions for Alkermes and 1 mentions for Atai Beckley. Alkermes' average media sentiment score of 0.53 beat Atai Beckley's score of 0.44 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 13 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ATAI or LQDA?

Liquidia has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 645.87 -$660.05M -$2.23 N/A Liquidia $158.32M 49.64 -$68.92M $0.14 631.21

Is ATAI or LQDA more profitable?

Liquidia has a net margin of 7.74% compared to Atai Beckley's net margin of -19,019.44%. Liquidia's return on equity of 46.82% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -19,019.44% -89.79% -63.58% Liquidia 7.74% 46.82% 7.06%

Does the media refer more to ATAI or LQDA?

In the previous week, Liquidia had 11 more articles in the media than Atai Beckley. MarketBeat recorded 12 mentions for Liquidia and 1 mentions for Atai Beckley. Liquidia's average media sentiment score of 0.69 beat Atai Beckley's score of 0.44 indicating that Liquidia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liquidia 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ATAI or LNTH?

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 645.87 -$660.05M -$2.23 N/A Lantheus $1.54B 4.27 $233.56M $4.15 24.35

Is ATAI or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Atai Beckley's net margin of -19,019.44%. Lantheus' return on equity of 29.32% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -19,019.44% -89.79% -63.58% Lantheus 18.05% 29.32% 15.00%

Does the media prefer ATAI or LNTH?

In the previous week, Lantheus had 24 more articles in the media than Atai Beckley. MarketBeat recorded 25 mentions for Lantheus and 1 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.44 beat Lantheus' score of 0.26 indicating that Atai Beckley is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 8 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Atai Beckley (ATAI) Competitors

$7.18 -0.01 (-0.07%)

As of 01:20 PM Eastern

Compare

ATAI vs. RDY, CRNX, ALKS, LQDA, and LNTH

Should you buy Atai Beckley stock or one of its competitors? MarketBeat compares Atai Beckley with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atai Beckley include Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Alkermes (ALKS), Liquidia (LQDA), and Lantheus (LNTH). These companies are all part of the "pharmaceuticals" industry.

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Atai Beckley's net margin of -19,019.44%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Atai Beckley has a consensus target price of $11.06, suggesting a potential upside of 54.09%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts plainly believe Atai Beckley is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27

In the previous week, Dr. Reddy's Laboratories had 8 more articles in the media than Atai Beckley. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 1 mentions for Atai Beckley. Dr. Reddy's Laboratories' average media sentiment score of 0.54 beat Atai Beckley's score of 0.44 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 19.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.82	$456M	$0.44	27.47
Atai Beckley	$4.09M	645.87	-$660.05M	-$2.23	N/A

Summary

Dr. Reddy's Laboratories beats Atai Beckley on 9 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Atai Beckley (NASDAQ:ATAI) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 19.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Crinetics Pharmaceuticals has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

Crinetics Pharmaceuticals presently has a consensus target price of $81.00, indicating a potential downside of 3.53%. Atai Beckley has a consensus target price of $11.06, indicating a potential upside of 54.09%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts clearly believe Atai Beckley is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27

In the previous week, Crinetics Pharmaceuticals had 11 more articles in the media than Atai Beckley. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 1 mentions for Atai Beckley. Crinetics Pharmaceuticals' average media sentiment score of 0.51 beat Atai Beckley's score of 0.44 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Atai Beckley	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crinetics Pharmaceuticals has a net margin of -2,747.18% compared to Atai Beckley's net margin of -19,019.44%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Crinetics Pharmaceuticals has higher revenue and earnings than Atai Beckley. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,149.82	-$465.32M	-$5.13	N/A
Atai Beckley	$4.09M	645.87	-$660.05M	-$2.23	N/A

Summary

Crinetics Pharmaceuticals beats Atai Beckley on 10 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Alkermes?

Atai Beckley (NASDAQ:ATAI) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Atai Beckley has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Atai Beckley presently has a consensus target price of $11.06, suggesting a potential upside of 54.09%. Alkermes has a consensus target price of $54.56, suggesting a potential upside of 11.02%. Given Atai Beckley's higher probable upside, equities analysts plainly believe Atai Beckley is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Alkermes had 40 more articles in the media than Atai Beckley. MarketBeat recorded 41 mentions for Alkermes and 1 mentions for Atai Beckley. Alkermes' average media sentiment score of 0.53 beat Atai Beckley's score of 0.44 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	13 Very Positive mention(s)	1 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	645.87	-$660.05M	-$2.23	N/A
Alkermes	$1.67B	4.94	$241.66M	$0.38	129.33

Alkermes has a net margin of 3.96% compared to Atai Beckley's net margin of -19,019.44%. Alkermes' return on equity of 4.15% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Alkermes	3.96%	4.15%	2.19%

Summary

Alkermes beats Atai Beckley on 12 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Liquidia?

Atai Beckley (NASDAQ:ATAI) and Liquidia (NASDAQ:LQDA) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Atai Beckley presently has a consensus target price of $11.06, indicating a potential upside of 54.09%. Liquidia has a consensus target price of $86.18, indicating a potential downside of 2.48%. Given Atai Beckley's higher possible upside, equities analysts plainly believe Atai Beckley is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

Liquidia has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	645.87	-$660.05M	-$2.23	N/A
Liquidia	$158.32M	49.64	-$68.92M	$0.14	631.21

Liquidia has a net margin of 7.74% compared to Atai Beckley's net margin of -19,019.44%. Liquidia's return on equity of 46.82% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Liquidia	7.74%	46.82%	7.06%

Atai Beckley has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Liquidia had 11 more articles in the media than Atai Beckley. MarketBeat recorded 12 mentions for Liquidia and 1 mentions for Atai Beckley. Liquidia's average media sentiment score of 0.69 beat Atai Beckley's score of 0.44 indicating that Liquidia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Liquidia beats Atai Beckley on 14 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Lantheus?

Atai Beckley (NASDAQ:ATAI) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Atai Beckley has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Atai Beckley currently has a consensus price target of $11.06, indicating a potential upside of 54.09%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 6.99%. Given Atai Beckley's higher probable upside, research analysts clearly believe Atai Beckley is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27
Lantheus	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

In the previous week, Lantheus had 24 more articles in the media than Atai Beckley. MarketBeat recorded 25 mentions for Lantheus and 1 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.44 beat Lantheus' score of 0.26 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	8 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a net margin of 18.05% compared to Atai Beckley's net margin of -19,019.44%. Lantheus' return on equity of 29.32% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Lantheus	18.05%	29.32%	15.00%

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	645.87	-$660.05M	-$2.23	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.15	24.35

Summary

Lantheus beats Atai Beckley on 11 of the 17 factors compared between the two stocks.

Get Atai Beckley News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATAI vs. The Competition

Export

Metric	Atai Beckley	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.64B	$11.50B	$6.81B	$12.94B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-3.22	791.51	279.92	25.45
Price / Sales	645.87	943.66	647.84	115.11
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	10.40	10.39	11.11	6.33
Net Income	-$660.05M	$2.80B	$3.48B	$347.60M
7 Day Performance	-0.07%	1.61%	2.04%	2.78%
1 Month Performance	38.25%	-3.16%	-3.16%	-2.36%
1 Year Performance	68.43%	155.11%	63.65%	20.74%

Atai Beckley Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATAI Atai Beckley	2.7336 of 5 stars	$7.18 -0.1%	$11.06 +54.1%	+72.2%	$2.64B	$4.09M	N/A	80
RDY Dr. Reddy's Laboratories	2.5766 of 5 stars	$12.07 +1.9%	N/A	-13.5%	$9.89B	$3.58B	27.43	27,527
CRNX Crinetics Pharmaceuticals	2.1514 of 5 stars	$83.76 +0.3%	$81.00 -3.3%	+200.9%	$8.81B	$7.70M	N/A	210	Earnings Report
ALKS Alkermes	2.9873 of 5 stars	$49.53 +1.1%	$54.56 +10.2%	+86.6%	$8.22B	$1.67B	130.35	2,050	Trending News Insider Trade Analyst Revision
LQDA Liquidia	3.1189 of 5 stars	$83.85 -0.3%	$86.18 +2.8%	+374.3%	$7.48B	$158.32M	598.97	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATAI) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atai Beckley (ATAI) Competitors

ATAI vs. RDY, CRNX, ALKS, LQDA, and LNTH

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Summary

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Summary

How does Atai Beckley compare to Alkermes?

Summary

How does Atai Beckley compare to Liquidia?

Summary

How does Atai Beckley compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atai Beckley (ATAI) Competitors

ATAI vs. RDY, CRNX, ALKS, LQDA, and LNTH

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Is RDY or ATAI more profitable?

Do analysts prefer RDY or ATAI?

Does the media favor RDY or ATAI?

Which has more risk and volatility, RDY or ATAI?

Do insiders and institutionals hold more shares of RDY or ATAI?

Which has stronger earnings and valuation, RDY or ATAI?

Summary

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Do insiders & institutionals have more ownership in CRNX or ATAI?

Which has more risk & volatility, CRNX or ATAI?

Do analysts rate CRNX or ATAI?

Does the media favor CRNX or ATAI?

Is CRNX or ATAI more profitable?

Which has higher valuation and earnings, CRNX or ATAI?

Summary

How does Atai Beckley compare to Alkermes?

Which has more risk and volatility, ATAI or ALKS?

Do analysts recommend ATAI or ALKS?

Do insiders & institutionals hold more shares of ATAI or ALKS?

Does the media refer more to ATAI or ALKS?

Which has better valuation & earnings, ATAI or ALKS?

Is ATAI or ALKS more profitable?

Summary

How does Atai Beckley compare to Liquidia?

Do analysts rate ATAI or LQDA?

Which has better valuation and earnings, ATAI or LQDA?

Is ATAI or LQDA more profitable?

Which has more volatility and risk, ATAI or LQDA?

Do insiders & institutionals believe in ATAI or LQDA?

Does the media refer more to ATAI or LQDA?

Summary

How does Atai Beckley compare to Lantheus?

Which has more volatility and risk, ATAI or LNTH?

Do institutionals & insiders believe in ATAI or LNTH?

Do analysts recommend ATAI or LNTH?

Does the media prefer ATAI or LNTH?

Is ATAI or LNTH more profitable?

Which has stronger earnings & valuation, ATAI or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools